Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELDN Eledon Pharmaceuticals	$2.63 +1.2%	$3.11	$2.38 ▼ $5.54	$157.49M	-0.15	996,877 shs	871,897 shs
GHRS GH Research	$12.79 +0.2%	$13.91	$6.00 ▼ $20.50	$665.44M	0.98	431,993 shs	167,506 shs
MGTX MeiraGTx	$8.17 -1.9%	$7.58	$3.85 ▼ $8.98	$656.58M	1.25	557,717 shs	717,859 shs
SIGA Siga Technologies	$8.50 -0.9%	$6.96	$4.95 ▼ $11.91	$608.65M	0.94	591,319 shs	466,389 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELDN Eledon Pharmaceuticals	0.00%	-2.95%	-29.87%	-8.36%	-2.59%
GHRS GH Research	0.00%	+3.06%	-25.86%	+16.48%	+29.98%
MGTX MeiraGTx	0.00%	+3.68%	-5.22%	+63.73%	+104.25%
SIGA Siga Technologies	0.00%	-5.13%	+26.87%	+41.90%	-28.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELDN Eledon Pharmaceuticals	1.8651 of 5 stars	3.5	1.0	0.0	2.6	1.7	0.0
GHRS GH Research	3.0397 of 5 stars	3.5	3.0	0.0	3.9	2.5	0.0
MGTX MeiraGTx	4.4892 of 5 stars	3.5	4.0	4.8	2.0	2.5	0.6
SIGA Siga Technologies	2.1585 of 5 stars	0.0	2.0	0.0	2.7	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELDN Eledon Pharmaceuticals	3.00	Buy	$10.00	280.23% Upside
GHRS GH Research	3.00	Buy	$32.00	150.20% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	193.76% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELDN, GHRS, SIGA, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
7/25/2025	ELDN Eledon Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
MGTX MeiraGTx	$33.28M	19.73	N/A	N/A	$0.87 per share	9.39
SIGA Siga Technologies	$179.64M	3.39	$0.84 per share	10.16	$2.92 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELDN Eledon Pharmaceuticals	-$36.18M	-$1.17	N/A	N/A	N/A	N/A	-55.66%	-37.92%	8/18/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.04	N/A	21.50	N/A	-415.39%	-239.38%	-59.35%	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.52	6.80	N/A	45.73%	40.52%	35.62%	N/A

Latest ELDN, GHRS, SIGA, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	ELDN Eledon Pharmaceuticals	-$0.23	-$0.13	+$0.10	-$0.13	N/A	N/A
8/14/2025	Q2 2025	MGTX MeiraGTx	-$0.52	-$0.48	+$0.04	-$0.48	$8.00 million	$3.69 million
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
GHRS GH Research	N/A	29.49	29.49
MGTX MeiraGTx	2.34	1.53	1.51
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELDN Eledon Pharmaceuticals	56.77%
GHRS GH Research	56.90%
MGTX MeiraGTx	67.48%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
ELDN Eledon Pharmaceuticals	12.30%
GHRS GH Research	41.60%
MGTX MeiraGTx	7.50%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

ELDN, GHRS, SIGA, and MGTX Headlines

Recent News About These Companies

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15 at 6:20 PM | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Rating Increased to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

August 7, 2025 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 24, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, GHRS, SIGA, and MGTX Company Descriptions

Eledon Pharmaceuticals NASDAQ:ELDN

$2.63 +0.03 (+1.15%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.62 -0.01 (-0.38%)

As of 08/15/2025 07:54 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

GH Research NASDAQ:GHRS

$12.79 +0.02 (+0.16%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$12.98 +0.20 (+1.52%)

As of 08/15/2025 07:36 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

MeiraGTx NASDAQ:MGTX

$8.17 -0.16 (-1.92%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.18 +0.02 (+0.18%)

As of 08/15/2025 07:12 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Siga Technologies NASDAQ:SIGA

$8.50 -0.08 (-0.93%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.50 0.00 (0.00%)

As of 08/15/2025 07:54 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time